[8-K] LB PHARMACEUTICALS INC Reports Material Event

Rhea-AI Filing Summary

LB Pharmaceuticals (LBRX) reported that it issued a press release announcing financial results for the quarter ended September 30, 2025. The company furnished the press release as Exhibit 99.1 via an 8-K.

The disclosure under Item 2.02 is expressly stated as “furnished,” not “filed,” which limits its application under Section 18 of the Exchange Act. The filing lists the company’s common stock on The Nasdaq Stock Market under the symbol LBRX, and is signed by Chief Executive Officer Heather Turner.

false 0001691082 0001691082 2025-11-06 2025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

LB Pharmaceuticals Inc

(Exact name of registrant as specified in its charter)

Delaware		001-42831		81-1854347
(state or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

One Pennsylvania Plaza, Suite 1025 New York, NY		10119
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (212) 605-0300

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		LBRX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished hereto as Exhibit 99.1.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained in this Item 2.02 and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated November 6, 2025.
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LB PHARMACEUTICALS INC
By:		/s/ Heather Turner
		Heather Turner Chief Executive Officer

Dated: November 6, 2025

FAQ

What did LBRX (LBRX) announce in this 8-K?

The company furnished a press release announcing financial results for the quarter ended September 30, 2025, as Exhibit 99.1.

Which exhibit contains LBRX’s Q3 2025 results press release?

Exhibit 99.1 contains the press release dated November 6, 2025.

Is the earnings information considered filed or furnished?

It is being furnished under Item 2.02 and is not deemed filed under Section 18 of the Exchange Act.

What is LBRX’s trading symbol and exchange?

The common stock trades on The Nasdaq Stock Market under the symbol LBRX.

Who signed the report for LBRX and in what capacity?

Chief Executive Officer Heather Turner signed the report on behalf of the company.

What is the date of the press release and the reporting period?

The press release is dated November 6, 2025, covering the quarter ended September 30, 2025.